BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/11/2026 11:23:54 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-11-12 02:09 |
|
Peer-Review Started |
|
2025-11-12 05:45 |
|
First Decision by Editorial Office Director |
|
2025-12-11 08:13 |
|
Return for Revision |
|
2025-12-11 08:13 |
|
Revised |
|
2025-12-12 18:50 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-12 02:45 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-12 09:21 |
|
Articles in Press |
|
2026-01-12 09:21 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-03 12:06 |
|
Publish the Manuscript Online |
|
2026-06-11 11:23 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Editorial |
| Article Title |
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Evidence for disease modification and therapeutic switching
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Vanishri Ganakumar, Cornelius J Fernandez and Joseph M Pappachan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph M Pappachan, FRCP, MD, MRCP, Professor, Senior Researcher, Faculty of Science, Manchester Metropolitan University, All Saints Building, Oxford Road, Manchester M15 6BH, Greater Manchester, United Kingdom. drpappachan@yahoo.co.in |
| Key Words |
Glucagon-like peptide-1 receptor agonists; Incretin polyagonists; Type 2 diabetes mellitus; Switching glucagon-like peptide-1 receptor agonist; Glycemic control |
| Core Tip |
Pharmacological manipulation of the incretin system has revolutionised the management of type 2 diabetes mellitus (T2DM) in the 21st century. The first few drug molecules in this group were the glucagon-like peptide-1 receptor agonists (GLP-1RA), which have been used for treating patients with T2DM in the past 2 decades. Newer molecules, including incretin polyagonists, with longer half-lives and dosing intervals, and better cardiometabolic outcomes, are being added recently. A study by Kassem et al published in the World Journal of Diabetes provides us with robust evidence from a large real-world study from Israel on the benefits of switching from an old GLP-1RA to a newer agent, the theme of this editorial. |
| Publish Date |
2026-06-11 11:23 |
| Citation |
Ganakumar V, Fernandez CJ, Pappachan JM. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Evidence for disease modification and therapeutic switching. World J Diabetes 2026; 17(6): 116477
|
| URL |
https://www.wjgnet.com/1948-9358/full/v17/i6/116477.htm |
| DOI |
https://doi.org/10.4239/wjd.116477 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
